Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Buildings: 2013-2015

Historic Buildings for Amphastar Pharmaceuticals (AMPH) over the last 1 years, with Jun 2015 value amounting to $67.8 million.

  • Amphastar Pharmaceuticals' Buildings rose 5.71% to $67.8 million in Q2 2015 from the same period last year, while for Jun 2015 it was $67.8 million, marking a year-over-year increase of 5.71%. This contributed to the annual value of $67.8 million for FY2014, which is 15.05% up from last year.
  • According to the latest figures from Q2 2015, Amphastar Pharmaceuticals' Buildings is $67.8 million, which was up 0.69% from $67.4 million recorded in Q1 2015.
  • Amphastar Pharmaceuticals' 5-year Buildings high stood at $67.8 million for Q2 2015, and its period low was $58.9 million during Q4 2013.
  • In the last 3 years, Amphastar Pharmaceuticals' Buildings had a median value of $67.1 million in 2014 and averaged $65.5 million.
  • Data for Amphastar Pharmaceuticals' Buildings shows a peak YoY rose of 15.05% (in 2014) over the last 5 years.
  • Quarterly analysis of 3 years shows Amphastar Pharmaceuticals' Buildings stood at $58.9 million in 2013, then rose by 15.05% to $67.8 million in 2014, then rose by 5.71% to $67.8 million in 2015.
  • Its Buildings stands at $67.8 million for Q2 2015, versus $67.4 million for Q1 2015 and $67.8 million for Q4 2014.